Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D07RKO
|
||||
Former ID |
DIB008813
|
||||
Drug Name |
MRX-6
|
||||
Synonyms |
CXCL10 gene inhibitor/phospholipase A2/ MIP 1 ligand inhibitor (contact dermatitis), Morria Biopharmaceuticals; IL 1 beta/IL-6/PGE 2 modulator (dermatological emulsion, contact dermatitis), Morria Biopharmaceuticals; Monocyte chemotactic protein 1/GM-CSF/TNF alpha ligand inhibitor (dermatological emulsion, contact dermatitis), Morria Biopharmaceuticals; Non-steroidal multifunctional anti-inflammatory drug (MFAID) (topical formulation, contact dermatitis), Morria
|
||||
Indication | Contact dermatitis [ICD9: 692; ICD10:L23, L24, L25] | Phase 2 | [1] | ||
Company |
Morria Biopharmaceuticals plc
|
||||
Target and Pathway | |||||
Target(s) | Phospholipase A2 | Target Info | Inhibitor | [2] | |
BioCyc Pathway | Phospholipases | ||||
KEGG Pathway | Glycerophospholipid metabolism | ||||
Ether lipid metabolism | |||||
Arachidonic acid metabolism | |||||
Linoleic acid metabolism | |||||
alpha-Linolenic acid metabolism | |||||
Metabolic pathways | |||||
Ras signaling pathway | |||||
Vascular smooth muscle contraction | |||||
Pancreatic secretion | |||||
Fat digestion and absorption | |||||
Pathway Interaction Database | Fc-epsilon receptor I signaling in mast cells | ||||
Reactome | Acyl chain remodelling of PC | ||||
Acyl chain remodelling of PE | |||||
Acyl chain remodelling of PI | |||||
WikiPathways | Glycerophospholipid biosynthesis | ||||
References | |||||
REF 1 | ClinicalTrials.gov (NCT02031445) Double-Blind, Trial to Evaluate the Safety and Efficacy of MRX-6 Cream 2%. U.S. National Institutes of Health. | ||||
REF 2 | A novel treatment of contact dermatitis by topical application of phospholipase A2 inhibitor: a double-blind placebo-controlled pilot study. Int J Immunopathol Pharmacol. 2007 Jan-Mar;20(1):191-5. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.